GlassScriptPhysician profile
Gener Cruz
NPI 1811612310
$3,364.68
in general payments reported to CMS, 2019-2025
20 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $90.77 · 2024: $1,563 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,364.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,179.02 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $523.61 | 2024-2025 | Trulance, Relistor, Xifaxan |
| Janssen Biotech, INC. | $279.87 | 2023-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $243.55 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $187.23 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $129.29 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Novo Nordisk INC | $108.10 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Madrigal Pharmaceuticals | $83.52 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $79.66 | 2024-2025 | Vowst |
| Ironwood Pharmaceuticals, INC | $79.60 | 2024 | |
| Lilly USA, LLC | $74.59 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $74.45 | 2024 | Suflave, Sutab |
| Pfizer INC. | $64.27 | 2024-2025 | |
| Orphalan INC | $55.71 | 2025 | Cuvrior |
| Gilead Sciences, INC. | $49.78 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $38.47 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $36.52 | 2023-2024 | Ocaliva |
| Qol Medical, LLC | $32.13 | 2024 | Sucraid |
| Celltrion USA INC. | $28.03 | 2025 | Vegzelma |
| Boston Scientific Corporation | $17.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gener Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.